• 1
    The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 39093918.
  • 2
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 9: 669687.
  • 3
    Aurora V, Winter JN. Current controversies in follicular lymphoma. Blood Rev. 2006; 20: 179200.
  • 4
    Meijerink JP. t(14;18), a journey to eternity. Leukemia. 1997; 11: 21752187.
  • 5
    Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4: 14701480.
  • 6
    Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs. 1997; 43: 10051037.
  • 7
    Barcos M, Bloomfield CD, Nissen NL, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003; 21: 515.
  • 8
    Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of the interferon in follicular lymphoma. J Clin Oncol. 2005; 23: 22152223.
  • 9
    Fisher RL, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller PT. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005; 23: 84478452.
  • 10
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22: 47114716.
  • 11
    Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006; 24: 15821589.
  • 12
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 28252833.
  • 13
    Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005; 23: 694704.
  • 14
    Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low grade non Hodgkin's lymphoma. Haematologica. 2001; 86: 951958.
  • 15
    Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001; 61: 51375144.
  • 16
    Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001; 7: 709723.
  • 17
    Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001; 114: 800809.
  • 18
    Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B cell chronic lymphocytes leukemia. Blood. 1999; 94: 28362843.
  • 19
    Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood. 1994; 83: 38003807.
  • 20
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 12441253.
  • 21
    Wittes RE. Common toxicity criteria for cancer clinical trials, version 1.0. In: MacDonaldJS, HallerDG, MayerRJ, editors. Manual of Oncologic Therapeutics. 3rd ed. Philadelphia: Lippincott; 1995: 445448.
  • 22
    Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 23
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719748.
  • 24
    Mann HB, Whitney DR. On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat. 1997; 18: 5060.
  • 25
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma prognostic index. Blood. 2004; 104: 12581265.
  • 26
    Luisi D, Luminari S, Amatetti C, et al. BACOP/FND first-line treatment of follicular lymphoma. Multicentric study of GISL. Preliminary result. Ann Oncol. 2004; 15( suppl 12): G17.
  • 27
    Klasa RJ, Meyer RM, Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non--Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 2002; 20: 46494654.
  • 28
    McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone and dexametasone: an effective regimen for indolent lymphoma. J Clin Oncol. 1996; 14: 12621268.
  • 29
    Santini G, Nati S, Spriano M, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica. 2001; 86: 282286.
  • 30
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 37253732.
  • 31
    Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood. 2006; 108: 32953301. Epub 2006 Jul 27..
  • 32
    Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.
  • 33
    McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND (Fludarabine, Mitoxantrone, Dexamethasone) chemotherapy and rituximab monoclonal antibody therapy, with interferon maintenance. J Clin Oncol. 2003; 22: 564. Abstract 2269.
  • 34
    Herold M, Pasold R, Srock S, et al. Result of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin'' lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood. 2004; 104: 169a. Abstract 584.
  • 35
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 14171423.
  • 36
    Keating MJ. O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 40794088.
  • 37
    Wijermans PW, Gerrits WB Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol. 1993; 50: 292296.